Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
July 10 2024 - 8:00AM
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a
biopharmaceutical company committed to enhancing people’s vision
and quality of life through the development and commercialization
of innovative therapies for wet age-related macular degeneration
(wet AMD), diabetic retinopathy, and other diseases and conditions
of the eye, today announced that a late-breaking abstract related
to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal
implant) for non-proliferative diabetic retinopathy (NPDR) was
accepted for presentation at the 42nd American Society of Retina
Specialists (ASRS) Annual Scientific Meeting being held July 17-20
in Stockholm, Sweden.
Presentation at ASRS Annual Scientific
Meeting:
- Title: Interim Safety and Efficacy Results From the
Phase 1 HELIOS Trial of Sustained-release Axitinib Implant
(OTX-TKI) for NPDR
Session Title: Diabetic Retinopathy
Symposium 2 Session
Date/Time: Thursday, July 18th 10:47 – 10:51 AM CEST Presenter:
Dilsher S. Dhoot, MD
About the HELIOS studyThe Phase 1 HELIOS trial
is a multi-center, double-masked, randomized (2:1), parallel group
study conducted in the U.S. The study was designed to evaluate
the safety, tolerability, and efficacy of AXPAXLI compared to a
sham control in subjects with moderately severe to severe
non-proliferative diabetic retinopathy (NPDR) without
center-involved diabetic macular edema (CI-DME). The primary
endpoint of the study is frequency of treatment emergent adverse
events (TEAEs). Secondary study endpoints include changes in the
diabetic retinopathy severity score (DRSS), changes in best
corrected visual acuity (BCVA) compared to baseline, changes in
central subfield thickness (CSFT) compared to baseline, and the
portion of subjects receiving rescue therapy.
About Ocular Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company committed to
enhancing people’s vision and quality of life through the
development and commercialization of innovative therapies for wet
age-related macular degeneration (wet AMD), diabetic retinopathy
(DR), and other diseases and conditions of the
eye. AXPAXLI™ (axitinib intravitreal implant, also known
as OTX-TKI), Ocular’s product candidate for retinal disease, is
based on its ELUTYX™ proprietary bioresorbable hydrogel-based
formulation technology. AXPAXLI is currently in a Phase 3 clinical
trial for wet AMD. The clinical portfolio also
includes PAXTRAVA™ (travoprost intracameral implant, also
known as OTX-TIC), currently in a Phase 2 clinical trial for the
treatment of open-angle glaucoma or ocular hypertension.
Ocular’s expertise in the formulation, development, and
commercialization of innovative therapies of the eye and the ELUTYX
platform supported the development and launch of its first
commercial drug product, DEXTENZA®, an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis.
Follow us on our website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered
trademarks of Ocular Therapeutix, Inc. AXPAXLI™,
PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks
of Ocular Therapeutix, Inc.
Investors & MediaOcular Therapeutix,
Inc.Bill SlatteryVice President, Investor
Relationsbslattery@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2023 to Aug 2024